Cessatech A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.cessatech.com
Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Cessatech A/S
- Target Recruit Count
- 150
- Registration Number
- NCT06364072
- Locations
- 🇪🇸
Hospital General Universitario Dr. Balmis, Alicante, Spain
🇪🇸Hospital Sant Joan de Deu, Barcelona, Spain
🇪🇸Universidad Autonoma de Madrid (UAM) - Hospital Universitario La Paz (HULP) -, Madrid, Spain
Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Cessatech A/S
- Target Recruit Count
- 220
- Registration Number
- NCT05508594
- Locations
- 🇩🇰
DanTrials, Copenhagen, NV, Denmark
Pharmacokinetic Study of Intranasal CT001 in Children 1-17 Years of Age Undergoing Elective Surgical Procedures
Phase 2
Completed
- Conditions
- Analgesia
- Interventions
- Combination Product: CT001
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Cessatech A/S
- Target Recruit Count
- 25
- Registration Number
- NCT04897750
- Locations
- 🇩🇰
Anæstesi- og Operationsafdelingen 4013 Juliane Marie Centeret, Copenhagen, Region H, Denmark
Study of CT001 in Healthy Volunteers
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Cessatech A/S
- Target Recruit Count
- 14
- Registration Number
- NCT04807335
- Locations
- 🇩🇰
Dantrials, Copenhagen, DK, Denmark
© Copyright 2025. All Rights Reserved by MedPath